No Data
No Data
October 1st [Today's investment strategy]
[Fisco Selected Stocks] [Material Stocks] Nexera Pharma <4565> 1226 yen (10/1) Drug discovery venture. Former Sosei Group. Its subsidiary Nexera Pharma Japan has announced the signing of a partnership agreement with Shionogi <4507> regarding the distribution and sales of the insomnia treatment drug "Cubick Tablets" in Japan, and resolved its sales efforts with Mochida Pharmaceutical <4534>. Shionogi will independently conduct distribution and sales activities in Japan. [Emerging Markets]
Pay attention to Zojirushi Mahobin and IBJ, Dai Seki, etc. are soft.
In the U.S. stock market on the 1st, the NY Dow Jones Industrial Average closed at 42,156.97, down 173.18 points, the Nasdaq Composite Index closed at 17,910.36, down 278.81 points, and the Chicago Nikkei 225 Futures closed at 38,030 yen, down 740 yen from the Osaka day session. The exchange rate was 1 dollar = 143.50-60 yen. In today's Tokyo market, Zojirushi Mahobin <7965> turned to profit by increasing operating profit for the third cumulative quarter by 6.5% from a 2.4% decrease in the previous period, and announced a share buyback of up to 1.59% of the issued shares.
Morozoff, Nichirei, etc. [5% rule]
<2217> Morozoff Co., Ltd., Mitsubishi UFJ Trust and Banking Co., Ltd. Shareholding 6.36% → 5.09%. Reporting obligation is due on August 12, 2024. <2721> J-Holdings Co., Ltd., Masakazu Nakatani Shareholding 9.30% → 9.30%. Reporting obligation is due on August 8, 2024. <2871> Nichirei Corporation, Mitsubishi UFJ Bank, Ltd. Shareholding -% → 5.17%. Reporting obligation is due on 202.
Insider increases its stake in Novarese(9160.JP) to 11.19%
On Aug 19, 株式会社IBJ submitted the Change Report to Ministry of Finance. The report shows that 株式会社IBJ increased their holdings in $Novarese(9160.JP)$, with their joint shareholding ratio up from 10.16%
Dentsu Group revised downwards to 107.1 billion yen in operating profit, from 135.4 billion yen on 24 December.
Dentsu Group (4324) announced a revision of its financial estimates for the fiscal year ending in December 2024, lowering its operating profit from 135.4 billion yen to 107.1 billion yen due to anticipated revenue deficits in Asia-Pacific regions such as China and Australia, resulting in impairment losses. Additionally, expenses related to the sale of its business in Russia, against the background of the Ukrainian invasion, have exceeded expectations. Plus evaluation: Skylark (3197), Medpeer (6095), Yonshan Holdings (3962).
Novarese: Confirmatory letter.
No Data
No Data